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Abstract
The tumor suppressor p53 is often inactivated in breast cancer cells because the overexpression of its repressors
(e.g., MDM2 and MDMX). Restoration of p53 activity by small molecules through counteracting p53 repressors
can lead to in vivo tumor regression and is therefore considered a promising strategy for treatments of cancer. Recent
efforts in high-throughput drug screening and rational drug design have identified several structurally diverse small-
molecule p53 activators, including a pseudourea derivative XI-011 (NSC146109). This small molecule strongly acti-
vates p53while selectively inhibiting growth of transformed cells without inducing genotoxicity, indicating its potential
as a drug lead for p53-targeted therapy. However, the mechanism(s) by which XI-011 activates p53 and the effects of
XI-011 on growth of breast cancer cells are currently unknown. Here, we report that XI-011 promoted breast cancer
cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes. Importantly, we
found that activationof p53by this smallmoleculewasachieved through anovelmechanism, that is, inhibition ofMDMX
expression. XI-011 repressed the MDMX promoter, resulting in down-regulation of MDMX messenger RNA level in
MCF-7 cells. In line with these results, XI-011 decreased the viability of breast cancer cells expressing low levels of
MDMX in a less-efficient manner. Interestingly, XI-011 acted additively with the MDM2 antagonist Nutlin-3a to inhibit
growth of breast cancer cells. We conclude that XI-011 belongs to a novel class of small-molecule p53 activators that
target MDMX and could be of value in treating breast cancer.
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Introduction
Breast cancer is one of the leading causes of death due to cancer. A
major factor contributing to the development of breast cancer is in-
activation of the tumor suppressor p53. p53 is the guardian of the
genome, and its main function is to maintain genetic stability on
oncogenic challenges by inducing cell cycle arrest, apoptosis, or senes-
cence [1,2]. Inactivation of p53 not only promotes tumorigenesis and
cancer progression but also confers breast cancer cells with an ability
to evade death induced by conventional therapeutic agents [3,4].
Not surprisingly, overexpression of major p53 repressors such as
MDM2 and MDMX occurs in more than 25% of breast cancers
[1]. Accordingly, restoration of p53 activity through counteracting
MDM2 orMDMX has been considered a promising strategy for breast
cancer treatments [5–7].
MDM2 inactivates p53 mainly through repressing its transcriptional
activity [8] and promoting its proteasomal degradation [9,10]. Because
such a regulation requires binding of MDM2 to p53, an effective strat-
egy to restore p53 activity in cancer cells is to dissociate the MDM2-
p53 complex. Indeed, it has been demonstrated that small molecules
(e.g., RITA, Nutlin-3a, MI-219) capable of disrupting the MDM2-
p53 interaction can activate p53, leading to in vivo tumor regres-
sion [11,12] while sensitizing cancer cells to conventional therapies
[13–15]. Notably, these designed small-molecule p53 activators are
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advantageous over conventional chemotherapeutic agents because they
do not exhibit genotoxicity [11,12]. However, these compounds seem
largely ineffective in cancer cells (e.g., MCF-7) that overexpress
MDMX, presumably because of their inability to prevent p53 from
MDMX binding [16–18]. As a homolog to MDM2 [19], MDMX
binds p53 and regulates p53 activity through repressing its transactiva-
tion activity [1] as well as promoting MDM2-mediated degradation
[20–23]. It is thus likely that MDMX-targeted agents could be more
effective in treating cancer cells expressing high levels of MDMX.
Indeed, a recent report showed that an MDMX-binding small mole-
cule activates p53 leading to death of MDMX-overexpressing retino-
blastoma cells [24]. Similar results were obtained with two peptides
that can interfere with the MDMX-p53 interaction [25,26]. Through
a cell-based high-content drug screening, we recently identified a
benzofuroxan derivative that can inhibit MDMX expression thereby
activating p53, leading to cancer cell death [27]. These results thus
indicate that MDMX-targeted agents could be of great value in treating
cancer, particularly breast cancer, which often overexpresses MDMX
rather than MDM2 [1].
NSC146109 ([10-methyl-9-anthryl]methyl imidothiocarbamate;
referred to as XI-011 thereafter) (Figure 1A) is a pseudourea deriva-
tive, and it was recently found to be a potent p53 activator through
a high-content drug screening [28]. XI-011 at 2 μM could increase the
activity of a p53 reporter by more than five-fold and was one of the
most potent p53-activating small molecules identified in that screen-
ing [28]. This small molecule was also shown to selectively decrease
viability of cancer cells without genotoxicity [28]. Interestingly, XI-011
seemed to be an active hit in a screening designed to search for tumor-
selective anticancer agents [29]. These results thus suggest that this
small-molecule p53 activator could be of value in further development
into a novel cancer therapeutic agent. However, the molecular mecha-
nism underlying the anticancer effects of XI-011 is poorly understood.
Here, we report that this small molecule could induce breast cancer
cells to undergo apoptosis—an effect distinct from the MDM2 inhibitor
Nutlin-3a. Importantly, we found that XI-011 activated p53 mainly
through inhibiting MDMX expression. This small molecule thus be-
longs to a new class of p53 activator that can induce apoptosis of breast
cancer cells through inhibiting MDMX expression.
Materials and Methods
Cell Lines and Reagents
Breast cancer cell linesMCF-7,MDA-MB-175VII, ZR-75-1, ZR-75-
30, HSS78T, BT474, and BT549 were cultured as recommended by
the American Type Culture Collection (Manassas, VA). We obtained
XI-011 (NSC146109) from the National Institutes of Health/National
Cancer Institute Developmental Therapeutics Program. Nutlin-3a and
RITA were purchased from Sigma-Aldrich (St Louis, MO) and Cayman
Chemical (Ann Arbor, MI), respectively. These compounds were dis-
solved in dimethyl sulfoxide (DMSO) at 20 μMand diluted intoworking
concentrations before use. Cell viability was measured with MTT assays.
Immunoblot Analysis and Cycloheximide Chase Assays
Immunoblot assays to determine protein levels were carried out as
previously described [30]. The following antibodies were used: p53
(DO-1), MDM2 (SMP-14), and poly(ADP-ribose)polymerase (PARP;
H-250) (from Santa Cruz Biotechnology, Santa Cruz, CA); MDMX
(from Bethyl Laboratories, Montgomery, TX); p21 (from BD Bio-
sciences, San Jose, CA); and β-actin (from Sigma-Aldrich). For cyclo-
heximide chase assays, cells were treated with or without 100 μg/ml of
cycloheximide (Sigma-Aldrich) for 0.5, 1, 2, and 3 hours and lysed for
immunoblot analysis as described [31].
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Cells were lysed in TRIzol (Invitrogen, Carlsbad, CA). Total RNAwas
prepared, reverse-transcribed, and subjected to real-time polymerase
chain reaction (PCR) assays using the ABI 7300 Real-time PCR System
as described previously [32]. The sequences of primers are as follows:
p21, forward 5′-CTGGAGACTCTCAGGGTCGAAA-3′ and reverse
5′-GATTAGGGCTTCCTCTTGGAGAA-3′; PUMA, forward 5′-
CCTGGAGGGTCCTGTACAATCT-3′ and reverse 5′-GCACCT-
AATTGGGCTCCATCT-3′; BAX, forward 5′-TGGAGCTGCAG-
AGGATGATTG-3′ and reverse 5′-AAACATGTCAGCTGCCACT-
CG-3′; PIG3, forward 5′-TTGAGGCATCTGGACATGTG-3′ and
reverse 5′-GGGTCAATCCCTCTGGGATAG-3′; and MDMX,
Figure 1. XI-011 activates p53 by increasing its stability. (A) The
chemical structure of XI-011. (B)MCF-7 cellswere treatedwithDMSO
(Ctrl), 10 μM Nutlin-3a, 1.0 μM RITA, or indicated amounts of XI-011
for 16 hours and lysed for immunoblot assays to measure the ex-
pression levels of p53, p21, and β-actin. (C) MCF-7 cells treated with
indicated amounts of XI-011 for 16 hours were lysed for RNA prepa-
ration. Total RNA was reverse-transcribed, and cDNA was subjected
to qRT-PCR assays for measuring levels of p21, PUMA, BAX, and
PIG3 mRNA. Data are depicted as mean ± SD values of three de-
terminations. *P < .05 versus the DMSO control (Student’s t test).
(D) After treatment with 0.5 μM of XI-011 for 16 hours, MCF-7 cells
were incubated with 100 μg/ml of cycloheximide. Cells were then
lysed at indicated time points and subjected to immunoblot assays.
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forward 5′-GCCTTGAGGAAGGATTGGTA-3′ and reverse
5′-TCGACAATCAGGGACATCAT-3′.
Flow Cytometry and Terminal Deoxynucleotidyl Transferase
dUTP Nick End Labeling Staining
Cells were fixed with cold 70% ethanol overnight and stained with
the propidium iodide solution (50 μg/ml; Sigma-Aldrich) containing
20 μg/ml RNase A at 37°C for 20 minutes for flow cytometry analy-
sis as described previously [33]. Data were analyzed using the FlowJo
software. For terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining, cells fixed with 4% paraformaldehyde
were subjected to dUTP labeling using In Situ Cell Death Detection
Kit TMR Red (Roche, Indianapolis, IN) and observed under a fluo-
rescence microscope. At least 300 cells were randomly chosen, and
numbers of TUNEL-positive cells were counted.
Short Hairpin RNA Knockdown
Short hairpin RNA (shRNA)–mediated gene knockdown was car-
ried out using a Lentivector-based system (pSIH-H1 shRNA Cloning
and Lentivector Expression system; System Biosciences, Mountain
View, CA) as described previously [34]. The targeted sequences for
MDMX, p53, and MDM2 were 5′-GTG ATG ATA CCG ATG
TAG A-3′, 5′-GAC TCC AGT GGT AAT CTA C-3′, and 5′-GGA
ATT TAG ACA ACC TGA A-3′ based on publications [16,35,36],
respectively. A firefly luciferase-targeted sequence (5′-CTT ACG
CTG AGT ACT TCG A-3′) was also cloned into the Lentivector as
a negative control.
Chromatin Immunoprecipitation Assays
Enrichment of RNA polymerase II (pol II) on the MDMX or
ATF3 promoter was determined by chromatin immunoprecipitation
assays as described previously [32] with modifications. Briefly, cells
were cross-linked with 1% formaldehyde for 10 minutes, followed by
lysis in a solution containing 25 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, and 0.5% sodium
deoxycholate. After sonication, lysates were incubated with 1 μg of the
RNA pol II antibody (N-20; Santa Cruz) or 1 μg of normal rabbit
IgG, at 4°C overnight. The chromatin-associated pol II was then pre-
cipitated with 30 μl of ssDNA-treated protein A agarose (Millipore,
Billerica, MA). The agarose was washed, and the bound chromatin
Figure 2. XI-011 induces apoptosis in breast cancer cells. (A) MCF-7 cells treated with 0.5 μM of XI-011, 5 μM of Nutlin-3a, or DMSO, for
24 and 48 hours were stained with propidium iodide and subjected to flow cytometry analysis. Numbers inserted in graphs indicate per-
centages of cells at different stages of cell cycle. (B, C) MCF-7 cells treated with XI-011 for 48 hours were subjected to TUNEL staining
assays. At least 300 cells were randomly chosen, and the numbers of TUNEL-positive cells were counted. (D) MCF-7 cells were treated
with indicated concentrations of XI-011 for 2 days and subjected to immunoblot assays to detect cleaved (CL-PARP) and full-length
(FL-PARP) PARP. (E) MCF-7 cells treated with 0.5 μM of XI-011 or DMSO for different days were subjected to flow cytometry to determine
percentages of apoptotic cells (sub-G0/G1 cells).
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was eluted with a buffer containing 100 mM NaHCO3 and 1% SDS.
After elution, chromatin solutions were treated with proteinase K and
RNase A and incubated at 65°C overnight to reverse cross-links. Pol
II-bound DNA were then purified using the QIAquick DNA purifica-
tion kit (Qiagen, Valencia, CA) and subjected to real-time PCR for quan-
titation [32]. The primers used for amplifying the MDMX promoter
(−96 to −31) were 5′-TGGTAGTGAGCTCAGCCTTTCTAG-3′
and 5′-GCCTCCGGAAACCATAGATG-3′. The primers for the
ATF3 promoter (−75 to +42) were 5′-TGCCAACACGGAGTAAAC-
GA-3′ and 5′-AGAGAAGAGAGCTGTGCAGTGC-3′ [37].
Results
XI-011 Activates p53 in Breast Cancer Cells
The pseudourea derivative XI-011 (Figure 1A) was identified as one
of the most potent active hits in a reporter-based screening for small-
molecule p53 activators [28].We therefore sought to determine whether
this small molecule could activate p53 in p53 wild-type MCF-7 breast
cancer cells. Toward this end, we treated MCF-7 cells with XI-011
and measured expression levels of p53 and its downstream target gene
p21 using immunoblot assays. As controls, we also treated cells with
Nutlin-3a and RITA—two well-characterized small-molecule p53 acti-
vators. Interestingly, XI-011 increased the cellular p53 protein level
as efficient as the two known p53 activators (Figure 1B). Moreover,
XI-011 treatments resulted in a dose-dependent increase in the p21
protein level, suggesting that p53 was indeed activated by the small
molecule (Figure 1B). To corroborate these results, we carried out quan-
titative reverse transcription–PCR (qRT-PCR) assays and found that
XI-011 dramatically increase messenger RNA (mRNA) levels of p21 as
well as p53-targeted proapoptotic genes including PUMA, BAX, and
PIG3 (Figure 1C). These results indicated that XI-011 could strongly
activate p53 in breast cancer cells. Moreover, XI-011 significantly ex-
tended the half-life of p53 (Figure 1D), consistent with a notion that this
small-molecule p53 activator could increase the stability of p53 in breast
cancer cells.
XI-011 Induces Apoptosis in Breast Cancer Cells
p53 activation can lead to cell cycle arrest or apoptotic cell death.
To determine the consequence of p53 activation induced by XI-011,
we treated MCF-7 cells with 0.5 μM of XI-011 and carried out flow
cytometry analysis to examine cell cycle progression. It has been shown
that activation of p53 by the MDM2 inhibitor Nutlin-3a results in
only cell cycle arrest but not apoptosis in cancer cells overexpressing
MDMX (e.g., MCF-7) [17]. Indeed, we found that Nutlin-3a induced
a significant decrease in the number of S-phase cells (Figure 2A). In
contrast, XI-011 did not appear to diminish the S-phase subpopulation
(Figure 2A). However, XI-011 treatments resulted in apparent accu-
mulation of cells in sub-G0/G1 phase (Figure 2A), suggesting that this
small molecule could rather induce MCF-7 cells to undergo apoptosis.
To confirm this important finding, we used TUNEL staining to specif-
ically label apoptotic cells. In line with the notion that XI-011 could in-
duce apoptosis, numbers of TUNEL-positive cells were largely increased
after XI-011 treatments (Figure 2, B and C). This finding was further
confirmed by the observations that cleavage of PARP—a biochemical
marker for apoptosis—was induced by XI-011 in a dose-dependent man-
ner (Figure 2D). Indeed, more than 40% of MCF-7 cells were apoptotic
after treatments with 0.5 μMXI-011 for 5 days (Figure 2E). These results
thus indicate that one of the major effects of XI-011 on breast cancer
cells was to induce apoptosis. This effect was in sharp contrast to the
effect conferred by Nutlin-3a, suggesting that XI-011 might activate
p53 through a mechanism distinct from the MDM2 inhibitor.
XI-011 Induces Apoptosis through Activating p53
To demonstrate that the apoptosis-inducing activity of XI-011 was
a consequence of p53 activation, we knocked down p53 expression
in MCF-7 cells using a p53-specific shRNA [27] and determined
PARP cleavage induced by XI-011. Indeed, XI-011–induced PARP
cleavage was largely impaired in p53-downregulated cells (Figure 3A).
Moreover, the XI-011–induced expression of proapoptotic genes (i.e.,
PUMA, BAX, and PIG3) was significantly diminished by knockdown
of p53 expression (Figure 3B).
XI-011 Activates p53 and Induces Apoptosis through
Inhibiting MDMX Expression
It has been suggested that the failure in induction of apoptosis by
Nutlin-3a in MCF-7 cells (Figure 3A) was likely due to MDMX over-
expression [17]. Because we have shown that XI-011 was distinct from
Nutlin-3a and could induceMCF-7 cells to undergo apoptosis, we tested
a hypothesis that XI-011 activates p53 through targeting MDMX. In-
terestingly, accompanied by p53 activation, theMDMX expression level
Figure 3. XI-011 induces apoptosis and proapoptotic gene expres-
sion through activation of p53. (A) MCF-7 cells infected with Lenti-
viruses expressing shRNA specific to p53 (shp53) or luciferase
(shLuc) were treated with 0.5 μM of XI-011 for 2 days and lysed for
immunoblot assays to detect cleaved (CL-PARP) and full-length
(FL-PARP) PARP. Intensities of CL-PARP and FL-PARP bands were
estimated by densitometry analysis and used for calculating the
CL-PARP to FL-PARP ratio (CL/FL-PARP) (shown below the blots).
(B) MCF-7 cells expressing shp53 or shLuc were treated with
0.5 μM of XI-011 for 16 hours and then subjected to qRT-PCR analy-
sis to measure levels of indicated mRNA. Data are depicted as the
mean ± SD values of three determinations. *P < .05 versus the
corresponding shLuc cells (Student’s t test).
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was dramatically decreased after MCF-7 cells were treated with XI-011
(Figure 4A). Inhibition of MDMX expression by XI-011 occurred 4 to
8 hours after treatment when p53 activation started to become notable
(Figures 4B and W1A). These results suggest a strong possibility that
p53 activation by XI-011 could be a consequence ofMDMX inhibition.
To explore this possibility, we knocked down MDMX expression in
MCF-7 cells with an MDMX-specific shRNA and determined p53 ac-
tivation by immunoblot analysis and qRT-PCR assays. Indeed, activa-
tion of p53 (Figure 4C ) and induction of expression of p53 target
genes (i.e., PUMA, BAX, and PIG3) (Figure 4D) were largely impaired
in cells expressing a low level of MDMX. Moreover, the cleavage of
PARP induced by XI-011 was also impaired by knockdown of MDMX
expression (Figure 4E). Furthermore, a small interfering RNA (siRNA)
specific toMDMXbut targeting a sequence different from the shRNAused
above also impaired p53 activation induced by XI-011 (Figure W1B).
These results thus indicate that XI-011 activated p53 and induced apop-
tosis through inhibiting MDMX expression. Of note, knockdown of
MDMX expression by shRNA alone seemed insufficient to activate
p53 and induce apoptosis (Figure 4, C and E , lane 5)—an observation
in agreement with several [16,17,38] but in contrast to other reports
[20,25]. The reason for this apparent discrepancy might be related to
the fact that the p53 activity is regulated by a complicated network and
thus effects of MDMX shRNA might be cell context–dependent [27].
Inhibition of MDMX Expression by XI-011 Is Not
a Consequence of p53 Activation
Having shown that XI-011 activated p53 through inhibiting MDMX
expression, we attempted to elucidate the mechanism by which XI-011
downregulated MDMX expression. Because MDM2 can bind MDMX
and drive its ubiquitination and proteolysis [39], p53 activated by DNA
damage might induce MDM2 expression leading to subsequent de-
crease in the MDMX expression level. Therefore, down-regulation of
MDMX expression by XI-011 might be a consequence of p53 activation
induced by DNA damage. To explore this possibility, we determined the
effects of XI-011 on MDMX expression in cells where p53 or MDM2
expression was knocked down by shRNAs. Interestingly, knockdown
of p53 expression or MDM2 expression did not affect or only slightly
affect XI-011–induced inhibition of MDMX expression (Figure 5, A
and B). Consistent with these observations, XI-011 could downregulate
MDMX expression in breast cancer cells (i.e., MDA-MB-231, BT474,
BT549) harboring functionally inactive p53 mutants (Figure 5C). These
results thus do not support the notion that XI-011 inhibited MDMX
expression through activating p53 and inducing MDM2 expression. In-
deed, XI-011 failed to prolong the half-life of MDMX (Figure W2)—a
result arguing against the possibility that XI-011 inhibited MDMX
expression through promoting MDM2-mediated proteolysis.
XI-011 Inhibits MDMX Gene Transcription
To explore the mechanism by which XI-011 inhibited MDMX
expression, we determined whether this small molecule might regulate
MDMX gene transcription. Toward this end, we first used a cell line
that harbors a firefly luciferase reporter driven by a MDMX promoter
[27] to determine the effects of XI-011 on MDMX promoter ac-
tivity. Interestingly, XI-011 decreased the promoter activity in a dose-
dependent manner (Figure 6A). Consistent with these results, the
MDMX mRNA level was downregulated by XI-011 (Figure 6B).
Figure 4. Activation of p53 and induction of apoptosis by XI-011 is a consequence of inhibition of MDMX expression. (A, B) MCF-7 cells
were treated with XI-011 as indicated and lysed for immunoblot assays for measuring MDMX, p53, and p21 expression levels. (C) MCF-7
cells infected with Lentiviruses expressing shLuc or shRNA specific to MDMX (shMDMX) were treated with varying amounts of XI-011 for
16 hours and subjected to immunoblot assays for p53 andMDMX expression. (D) MCF-7 cells expressing shMDMX or shLucwere treated
0.5 μM of XI-011 and subjected to qRT-PCR analysis to measure levels of indicated mRNA. Data are depicted as the average ± SD values
of three determinations. *P < .05 versus the corresponding shLuc cells (Student’s t test). (E) MCF-7 cells expressing shLuc or shMDMX
were treated with indicated amounts of XI-011 for 2 days and subjected to immunoblot assays to detect cleaved and full-length PARP.
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Because promoter occupancy of RNApol II reflects the transcription rate
of a gene, we carried out chromatin immunoprecipitation assays using
an anti–pol II antibody to confirm that XI-011 indeed intervened in
MDMX gene transcription. Treatments of MCF-7 cells with XI-011 re-
sulted in a dramatic reduction in the amounts of pol II associated with
the MDMX promoter (Figure 6C). Such a reduction was unlikely an
artifact due to loss of DNA mass in the experimental manipulations
because amounts of pol II associated with the promoter of ATF3,
a control gene whose expression was not inhibited by XI-011 (data
not shown), was not dramatically reduced in the samples treated
with the small molecule (Figure 6C ). These results thus confirmed
that XI-011 inhibited MDMX expression through repressing MDMX
gene transcription.
XI-011 Decreases Viability of Breast Cancer Cells
We have shown that XI-011 could activate p53 and induced apop-
tosis, which might in turn lead to a decrease in cell viability. Indeed,
XI-011 dramatically decreased viability of MCF-7 cells (Figure 7B). An
interesting question was surfaced as to whether efficacies of XI-011 to
decrease cell viability were reduced in breast cancer cells expressing low
levels of MDMX. To address this question, we treated three other
breast cancer cell lines (i.e., ZR-75-1, ZR-75-30, and MD-175VII)
that harbor a wild-type p53 gene but express a low level of MDMX
with XI-011. As expected, XI-011 increased the p53 level in these cell
lines, but the overall p53 level was much lower than MCF-7 cells after
treatments (Figure 7A). Consistent with low p53 levels, XI-011 seemed
less effective in decreasing viability of the three cell lines that express low
levels of MDMX compared with MCF-7 cells (Figure 7B). These re-
sults are in support of the notion that XI-011 activated p53 and de-
creased cell viability mainly through inhibiting MDMX expression.
Of note, the effects of XI-011 on cell viability did not correlate well
with MDMX levels in the three cell lines expressing low levels of
MDMX, probably because of the difference in cell contexts.
XI-011 Acts Additively with Nutlin-3a to Inhibit Growth
of Breast Cancer Cells
The MDM2 inhibitor Nutlin-3a can disrupt the p53-MDM2 inter-
action leading to p53 activation and cell death in many plural cancer
cell lines [11] but fail to induce apoptosis in cancer cells (e.g., MCF-7)
expressing high levels of MDMX [17–19]. Because we have shown
that XI-011 could inhibit MDMX expression, we explored a possibility
that XI-011 acts in concert with Nutlin-3a to inhibit growth of breast
cancer cells. Previously, we have developed a cell line that expresses a
luciferase reporter gene under control of a p53-responsive promoter (P2
promoter) and thus expression of the luciferase gene reflects the activity
Figure 5. Inhibition of MDMX expression by XI-011 is not caused by
p53 activation or MDM2 induction. (A, B) MCF-7 cells infected with
shLuc, shp53 (A) or shRNA specific to MDM2 (shMDM2) (B) were
treatedwith indicated amounts of XI-011 for 16 hours and then lysed
for immunoblot assays. (C) MCF-7 and indicated p53 mutant cells
were treated with 0.5 μM of XI-011 for 16 hours and subjected to
immunoblot assays. Both shorter exposure (short exp.) and longer
exposure (long exp.) were shown for the MDMX blot.
Figure 6. XI-011 inhibits MDMX gene transcription. (A) A reporter
cell line carrying a stably integrated firefly luciferase gene under con-
trol of aMDMX promoter [27] were treated with various amounts of
XI-011 for 16 hours and lysed for luciferase activity assays. (B) MCF-7
cells treated with indicated amounts of XI-011 were subjected to
qRT-PCR assays to measure MDMX mRNA levels. (C) MCF-7 cells
were treated with DMSO or indicated concentrations of XI-011 for
16 hours and then subjected to chromatin immunoprecipitation
assays using an antibody against RNA pol II. The DNA associated
with pol II were purified and quantified by real-time PCR.
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of p53 in the cells [27]. We therefore treated these cells with XI-011,
Nutlin-3a, or both compounds, and performed luciferase activity assays
to determine their effects on p53 activation. As expected, both XI-011
and Nutlin-3a increased the p53 reporter activity (Figure 8A). Interest-
ingly, p53 activation was enhanced by coadministration of these two
compounds (Figure 8A). As a control, expression of a luciferase reporter
driven by a p53-nonresponsive promoter (P1 promoter) [27] was not
affected by treatments with these agents (Figure 8A). These results,
which were confirmed by immunoblot assays (Figure 8B), suggest that
XI-011 acted additively, but not synergistically, with Nutlin-3a to ac-
tivate p53. Consistent with these results, the viability of MCF-7 cells
was decreased by XI-011 and Nutlin-3a in an additive manner
(Figure 8C). These results are in line with our previous conclusion that
an MDMX-targeting small molecule can cooperate with a MDM2
inhibitor to activate p53 and induce death of malignant cells [27].
Discussion
The pseudourea derivative XI-011 was previously found to activate p53
and specifically inhibit growth of transformed cells through unbiased,
high-content drug screening [28,29]. In this study, we reported for the
first time that this small molecule could activate p53 through inhibiting
MDMX expression in various breast cancer cell lines. This notion was
supported by our observations that both XI-011–induced p53 activation
and subsequent decrease in cell viability were largely impaired in cells
expressing low levels of MDMX. Our findings thus add XI-011 to a
short list of small molecules that can activate p53 through counteracting
MDMX functions in cancer cells. Previously, only two small molecules
have been found to targetMDMX, that is, SJ-172250, a compound that
binds MDMX and blocks the p53-MDMX interaction [24], and
XI-006, a benzofuroxan derivative that inhibits MDMX expression
[27]. Given that MDMX is a major p53 repressor and overexpressed
in nearly 20% of breast cancers [38], the results from this study are in
strong support of a notion that therapeutic agents targeting MDMX
overexpression in malignant cells could be of benefit to millions of
patients with cancer [27].
Distinct from MDM2, MDMX contains a RING domain but lacks
E3 ubiquitin ligase activity [1]. It is thus often assumed that bind-
ing of MDMX to p53 does not affect the p53 stability [1,40]. How-
ever, recent evidence indicates that MDMX can dimerize with MDM2
Figure 7. XI-011 decreases the viability of breast cancer cells ex-
pressing a low level of MDMX in a less-efficient manner. (A) Indi-
cated cells treated with DMSO or 0.5 μM of XI-011 were subjected
to immunoblot assays for MDMX and p53 expression. (B) Indicated
cells were treated with various amounts of XI-011 for 4 days and
subjected to MTT assays for measuring cell viability.
Figure 8. XI-011 decreases the viability of breast cancer cells in
collaboration with Nutlin-3a. (A) Cells carrying a luciferase gene
driven by a p53-responsive (P2) or p53-nonresponsive (P1) promoter
were treated with 0.2 μM of XI-011, 5 μM of Nutlin-3a, or both
agents, for 6 hours, and then lysed for luciferase activity assays.
(B) MCF-7 cells were treated with 0.2 μM of XI-011, 5 μM of
Nutlin-3a, or both agents, for 24 hours, and lysed for immunoblot
assays to measure levels of MDMX, p53, and PARP. (C) MCF-7 cells
were treated for 4 days with various amounts of Nutlin-3a in the ab-
sence or presence of 0.2 μM of XI-011 and then subjected to MTT
assays for measuring cell viability. Data are depicted as mean ±
SD values of three determinations.
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through the RING domains [7], thereby promoting efficient ubiquiti-
nation and degradation of p53 mediated by MDM2 [21–23,41]. This
most recent model predicts that down-regulation ofMDMX expression
would lead to stabilization of the tumor suppressor. Indeed, we found
that XI-011, like another MDMX inhibitor characterized in our previ-
ous report [27], dramatically increased the stability of p53 (Figure 1D).
This effect was unlikely caused by an activity aside from inhibition of
MDMX expression because knockdown of MDMX expression by a
specific shRNA or siRNA could compromise XI-011–induced increase
in the p53 level in breast cancer cells (Figure 4C ). However, SJ-
172250, a small molecule that counteracts MDMX through disrupting
the p53-MDMX interaction, only slightly increases the cellular p53 level
in retinoblastoma cells [24]. Because SJ-172250 intervenes in neither
the p53-MDM2 interaction nor the MDMX-MDM2 interaction
[24], MDMX might bind to MDM2 thereby retaining its capability
to promote MDM2-mediated p53 degradation after SJ-172250 treat-
ments. Conversely, down-regulation of the cellular MDMX level
by XI-011 could limit the availability of MDMX to both p53 and
MDM2, resulting in efficient stabilization of p53. In this regard,
XI-011 and other small molecules inhibitory for MDMX expression
(e.g., XI-006) [27] might be more potent in activating p53 and thus
could lead to better therapeutic outcomes than small molecules target-
ing the p53-MDMX interaction (e.g., SJ-172250). It is important to
note that XI-011, like XI-006 reported previously [27], could effi-
ciently decrease the viability of breast cancer cells harboring mutant
p53 (data not shown). These effects were not unexpected, and likely
achieved through targeting MDMX for its functions independent of
p53. Indeed, it has been documented that MDMX regulates other
members of the p53 family including p63 and p73 [42–44], as well
as Smad transactivation [45].
DNA damage induced by small molecules can activate p53, which
may in turn induce MDM2 expression leading to subsequent degra-
dation of MDMX [39]. Although XI-011 contains an anthracene
ring and structurally resembles a DNA intercalator [29,46], this small
molecule does not induce DNA damage at concentrations (20 μM)
much higher than the concentrations (0.2-1 μM) at which p53 was
strongly activated [28], arguing against the possibility that inhibition
of MDMX expression by XI-011 was a consequence of p53 activation
due to DNA damage. Indeed, although XI-011 did not alter the half-
life of MDMX, this small-molecule p53 activator could downregulate
MDMX expression in breast cancer cells harboring mutant p53 genes
or in cells where p53 or MDM2 expression was knocked down by
shRNA (Figure 5). Our results strongly suggest that XI-011 inhibited
MDMX expression rather through inhibiting MDMX gene transcrip-
tion. In support of this notion, XI-011 not only decreased theMDMX
mRNA level but also reduced the amounts of pol II associated with
the MDMX promoter (Figure 6). Given that XI-011 may bind DNA
[46], it might be that this small molecule binds to the MDMX pro-
moter thereby either directly preventing pol II from binding to the
promoter or blocking recognition of cis-regulatory elements by tran-
scription factors. However, XI-011 is not a general transcription inhib-
itor because expression of p53 target genes was induced, rather than
inhibited, by the small molecule. Further exploration of the mecha-
nism(s) by which XI-011 inhibits MDMX transcription is difficult,
given that the cis-/trans-regulatory elements regulating MDMX tran-
scription remain unclear.
Interestingly, pseudourea (NSC56054), the parent compound of
XI-011, was found to be cytotoxic to malignant cells and entered clini-
cal trials [47]. This compound was soon withdrawn from clinical test-
ing because of severe toxicity [47]. Because XI-011 does not induce
DNA damage at concentrations sufficient to activate p53 [28], and
because XI-011 seems to selectively inhibit growth of transformed cells
[29], this novel MDMX inhibitor might be more tolerant than pseudo-
urea and thus could serve as a lead compound for further development
into a therapeutic agent for breast cancer treatments.
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Figure W2. XI-011 does not alter the half-life of MDMX. MCF-7 cells treated with or without 0.5 μM of XI-011 for 16 hours were incubated
with 100 μg/ml cycloheximide (CHX). Cells were then harvested at indicated time points and lysed for immunoblot assays for MDMX and
β-actin expression (left panel). Densitometry analysis was performed to estimate relative MDMX expression levels (right panel).
Figure W1. Activation of p53 by XI-011 is a consequence of inhibition ofMDMX expression. (A) Relative expression levels of MDMX and
p53 in Figure 4B were quantified using the Image J software. (B) MCF-7 cells transfected with 50 nM of a MDMX-specific siRNA
(5′-AAAACUGCCGCUUUUGAAGAU-3′) or a control siRNA (specific to firefly luciferase) were treated with 0.5 μM of XI-011 for 12 hours
and then lysed for immunoblot assays for p53 and MDMX expression.
